Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (referred to in the metadata as IGC Pharma, Inc.) on November 29, 2017. The report details the entry into a material definitive agreement to facilitate an equity financing program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The primary financial figure disclosed is the authorization to sell up to $10,000,000 of common stock through an At-the-Market (ATM) offering.
- Offering Size: Up to $10,000,000
- Agent Commission: 4.0% of gross proceeds
- Stock Par Value: $0.0001 per share
Material Changes
The material change reported is the execution of a Sales Agreement with The Benchmark Company, LLC on November 29, 2017. This agreement establishes an ATM facility allowing the company to sell shares directly on the NYSE American or other trading markets. The agreement is set to automatically terminate on November 29, 2019, unless terminated earlier.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future performance. Key terms and contingencies include:
- Suspension Rights: The Company or Benchmark may suspend the offering upon notice.
- Private Sales: Benchmark may sell shares in privately negotiated transactions only with prior written approval from the Company.
- Legal Framework: Shares are issued pursuant to an effective Form S-3 shelf registration statement (File No. 333-201822).
- Indemnification: The Company has agreed to indemnify Benchmark against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the current share price to estimate the number of shares required to reach the $10,000,000 cap.
- Review the effective Form S-3 registration statement (File No. 333-201822) for existing dilution and use of proceeds.
- Monitor future 8-K filings or quarterly reports for actual sales volumes and proceeds generated under this ATM agreement.
- Confirm the company's current cash position to assess the immediate necessity of this financing.